Neoadjuvant immune checkpoint inhibitors in cancer, current state of the art

被引:9
|
作者
Le Saux, Olivia [1 ]
Lounici, Yasmine [1 ]
Wajda, Pauline [1 ]
Barrin, Sarah [1 ]
Caux, Christophe [1 ]
Dubois, Bertrand [1 ]
Ray-Coquard, Isabelle [2 ]
机构
[1] Ctr Leon Berard, Ctr Rech Cancerol Lyon, CNRS 5286, Inserm 1052, F-69008 Lyon, France
[2] Ctr Leon Berard, Dept Med Oncol, 28 Rue Laennec, F-69008 Lyon, France
关键词
Immunotherapy; Cancer; Neoadjuvant; Preclinical data; BREAST-CANCER; IPILIMUMAB; THERAPY; CHEMOTHERAPY; NIVOLUMAB; BLOCKADE; OVEREXPRESSION; PEMBROLIZUMAB; CARBOPLATIN; PACLITAXEL;
D O I
10.1016/j.critrevonc.2020.103172
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Immunotherapy has been a revolution in cancer management in the metastatic setting. This has led to a prompt evaluation of such therapies in earlier stages. This article discusses the still limited amount of data finding the rationale to assess such therapy in this setting and reviews preclinical and clinical data available. Overall, neoadjuvant immunotherapy is a promising approach for the treatment of cancers and the rationale supporting its use is strong. Neoadjuvant immunotherapy resulted, in the majority of clinical trials, in improved pathologic complete response rates with a favorable toxicity profile and no delay in surgery. Various regimens were effective: inhibitory immune check-point blockers (IICPB) alone, combination of PD-1 and CTLA-4 inhibitors, combination of chemotherapy (CT) and IICPB, phased CT and IICPB (either IICPB before CT or IICPB after CT). Yet the question whether neoadjuvant immunotherapy will benefit to patients in terms of disease-free and, ultimately, overall survival remains unknown.
引用
收藏
页数:11
相关论文
共 50 条
  • [1] Immune Checkpoint Inhibitors in Urothelial Bladder Cancer: State of the Art and Future Perspectives
    Roviello, Giandomenico
    Catalano, Martina
    Santi, Raffaella
    Palmieri, Valeria Emma
    Vannini, Gianmarco
    Galli, Ilaria Camilla
    Buttitta, Eleonora
    Villari, Donata
    Rossi, Virginia
    Nesi, Gabriella
    [J]. CANCERS, 2021, 13 (17)
  • [2] Ovarian Cancer in the Era of Immune Checkpoint Inhibitors: State of the Art and Future Perspectives
    Maiorano, Brigida Anna
    Maiorano, Mauro Francesco Pio
    Lorusso, Domenica
    Maiello, Evaristo
    [J]. CANCERS, 2021, 13 (17)
  • [3] The Role of Immune Checkpoint Inhibitors in Metastatic Pancreatic Cancer: Current State and Outlook
    Tran, Linh Chi
    Ozdemir, Berna C.
    Berger, Martin D.
    [J]. PHARMACEUTICALS, 2023, 16 (10)
  • [4] Immune Checkpoint Inhibitors in the Treatment of Renal Cancer: Current State and Future Perspective
    Lavacchi, Daniele
    Pellegrini, Elisa
    Palmieri, Valeria Emma
    Doni, Laura
    Mela, Marinella Micol
    Di Maida, Fabrizio
    Amedei, Amedeo
    Pillozzi, Serena
    Carini, Marco
    Antonuzzo, Lorenzo
    [J]. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2020, 21 (13) : 1 - 21
  • [5] Current status of immune checkpoint inhibitors for gastric cancer
    Koji Kono
    Shotaro Nakajima
    Kosaku Mimura
    [J]. Gastric Cancer, 2020, 23 : 565 - 578
  • [6] Current status of immune checkpoint inhibitors for gastric cancer
    Kono, Koji
    Nakajima, Shotaro
    Mimura, Kosaku
    [J]. GASTRIC CANCER, 2020, 23 (04) : 565 - 578
  • [7] Current status of cancer immunotherapy with immune checkpoint inhibitors
    Lee, Myung Ah
    [J]. JOURNAL OF THE KOREAN MEDICAL ASSOCIATION, 2021, 64 (05): : 326 - 331
  • [8] The Effectiveness of Immune Checkpoint Inhibitors in the Neoadjuvant and Post-Neoadjuvant Breast Cancer Settings
    Pusztai, Lajos
    [J]. CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2022, 20 (09) : 552 - 555
  • [9] The current state of immune checkpoint inhibitors in the first-line treatment of renal cancer
    El Rassy, Elie
    Abboud, Rita Maria Khoury
    Ibrahim, Nathalie
    Assi, Tarek
    Aoun, Fouad
    Kaftan, Joseph
    [J]. IMMUNOTHERAPY, 2018, 10 (12) : 1047 - 1052
  • [10] Research progress on immune checkpoint inhibitors in neoadjuvant therapy for gastric cancer
    Wenting Li
    Shiying Yu
    [J]. Oncology and Translational Medicine, 2022, (02) : 74 - 82